supported by Zhejiang Major R&D programs(2021C03042);Key R&D Program of Zhejiang Respiratory Disease(2023C03069);Zhejiang Provincial Clinical Research Center for Respiratory Disease(2022E50005).
Osimertinib,a third-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),has demonstrated significant clinical benefits in the treatment of EGFR-mutated non-small cell lung cancer(NSCLC).How...